A study by Bresee and Rapaport (59) suggests that serum-soluble IL-2R levels may represent a biomarker for patients with treatment-resistant psychosis, and a positive correlation between the severity of symptoms and the IL-2R underlines its involvement in schizophrenia. The gene discussed is IL2RA; the disease is psychotic disorder.